Infliximab (N = 5174) | Golimumab (N = 2843) | p value | |
Overall cohort | |||
Dose escalation*, % | 49.46 | 4.89 | < 0.0001 |
Dose increase, % | 39.49 | 3.17 | < 0.0001 |
Frequency increase, % | 29.15 | 1.79 | < 0.0001 |
Discontinuation, % | 73.33 | 79.85 | < 0.0001 |
Biologic Medicare-approved amounts, day 0–546, $ | |||
All biologics** | |||
LS mean (95% CI) | 26,934 (26,441–27,435) | 35,512 (34,849–36,187) | < 0.0001 |
Index biologic | |||
LS mean (95% CI) | 21,216 (20,737–21,706) | 28,146 (27,497–28,810) | < 0.0001 |
Biologic Medicare-approved amounts, day 183–546, $ | |||
All biologics** | |||
LS mean (95% CI) | 16,401 (15,699–17,135) | 20,512 (19,615–21,450) | < 0.0001 |
Index biologic | |||
LS mean (95% CI) | 11,488 (10,813–12,205) | 14,055 (13,213–14,951) | < 0.0001 |
Persistent cohort (no switch or gap > 10 weeks) | N = 1380 | N = 573 | |
Dose escalation*, % | 71.96 | 7.85 | < 0.0001 |
Dose increase, % | 58.55 | 5.24 | < 0.0001 |
Frequency increase, % | 45.00 | 2.97 | < 0.0001 |
Biologic Medicare-approved amounts, day 0–546, $ | |||
Index biologic | |||
LS mean (95% CI) | 34,671 (33,891–35,470) | 43,940 (42,849–45,058) | < 0.0001 |
Biologic Medicare-approved amounts, day 183–546, $ | |||
Index biologic | |||
LS mean (95% CI) | 22,877 (22,301–23,467) | 27,454 (26,692–28,238) | < 0.0001 |